In vivo 19F MR imaging and spectroscopy for the BNCT optimization.
The aim of this study was to evaluate in vivo the boron biodistribution and pharmacokinetics of 4-borono-2-fluorophenylalanine ((19)F-BPA) using (19)F MR Imaging ((19)F MRI) and Spectroscopy ((19)F MRS). The correlation between the results obtained by both techniques, (19)F MRI on rat brain and (19)F MRS on blood samples, showed the maximum (19)F-BPA uptake in C6 glioma model at 2.5h after infusion determining the optimal irradiation time. Moreover, the effect of L-DOPA as potential enhancer of (19)F-BPA tumour intake was assessed using (19)F MRI.
Porcari
P
P
CNR-INFM SOFT, Department of Physics, Sapienza University of Rome, Piazzale Aldo Moro 2, Rome, Italy. paola.porcari@roma1.infn.it
Capuani
S
S
D'Amore
E
E
Lecce
M
M
La Bella
A
A
Fasano
F
F
Migneco
L M
LM
Campanella
R
R
Maraviglia
B
B
Pastore
F S
FS
D000818:Animals; D001896:Boron Compounds / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016754:Boron Neutron Capture Therapy / Q000379:methods*; D001932:Brain Neoplasms / Q000378:metabolism / Q000532:radiotherapy; D045744:Cell Line, Tumor; D005461:Fluorine / Q000032:analysis* / Q000493:pharmacokinetics*; D005910:Glioma / Q000378:metabolism / Q000532:radiotherapy; D066298:In Vitro Techniques; D008279:Magnetic Resonance Imaging / Q000379:methods*; D009682:Magnetic Resonance Spectroscopy / Q000379:methods*; D008297:Male; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D011838:Radiation-Sensitizing Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D014018:Tissue Distribution
D001896:Boron Compounds; D011838:Radiation-Sensitizing Agents; C072915:4-borono-2-fluorophenylalanine; D005461:Fluorine; D010649:Phenylalanine